Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia-Reference-Cited by-同舟云学术

Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia

Published:2016-08-10 Issue:12 Volume:57 Page:2739-2751
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Caldemeyer Lauren,Akard Luke P.

Funder

Novartis Pharmaceuticals

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://tandfonline.com/doi/pdf/10.1080/10428194.2016.1198959

Reference96 articles.

1. NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia. Version 1.2016. [Internet]. Fort Washington, PA: National Comprehensive Cancer Network; 2015 Sept 9 [cited 2016 May 23]; Available from: www.nccn.org/professionals/physician_gls/pdf/cml.pdf.

2. Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

3. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years

4. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

5. Discontinuation of Imatinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Complete Molecular Response: Update Results of the STIM Study

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of contraception methods in chronic myeloid leukemia patients: A Turkish multicenter study;Journal of Oncology Pharmacy Practice;2024-09-02

2. Successful maintenance of a sustained molecular response in CML patients receiving low-dose tyrosine kinase inhibitors;Therapeutic Advances in Hematology;2024-01

3. Identification of key microRNAs as predictive biomarkers of Nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial;Leukemia;2022-08-23

4. Copper-imidazo[1,2-a]pyridines differentially modulate pro- and anti-apoptotic protein and gene expression in HL-60 and K562 leukaemic cells to cause apoptotic cell death;Biochimica et Biophysica Acta (BBA) - Molecular Cell Research;2022-01

5. Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice?;Critical Reviews in Oncology/Hematology;2021-01